Abstract:The emergence of drug resistance is a recurrent theme in targeted cancer therapies; thus, the understanding and conquering of drug resistance have become focal points in precision cancer medicine. While the biochemical and genetic mechanisms underlying drug resistance are diverse and complex, the state-of-art technologies (high-throughput sequencing, functional genomics, model systems, etc.) leading to the understanding of such mechanisms have been a consistent force driving the advancement of this field. Although many genes have been found to impact drug resistance, the limited convergence from multiple studies indicates that we are still at the beginning stage of unearthing the entire drug-resistance repertoire. New genomic technologies, preclinical models, and computational methodologies are poised to further accelerate the development of this new field. A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. A major obstacle in precision cancer medicine is the inevitable resistance to targeted therapies. Tremendous effort and progress has been made over the past few years to understand the biochemical and genetic mechanisms underlying drug resistance, with the goal to eventually overcome such daunting challenges. Diverse mechanisms, such as secondary mutations, oncogene bypass, and epigenetic alterations, can all lead to drug resistance, and the number of known involved genes is growing rapidly, thus providing many possibilities to overcome resistance. The finding of these mechanisms and genes invariably requires the application of genomic and functional genomic approaches to tumors or cancer models. In this review, we briefly highlight the major drug-resistance mechanisms known today, and then focus primarily on the technological approaches leading to the advancement of this field. the CRISPR-Cas system functions as an adaptive immune system in bacteria and has been adapted to engineer mammalian genomes in an efficient manner. The CRISPR-Cas9 screen has become a powerful functional genetic screening approach suitable for mammalian genetic models, including human cancer cells and mouse models. a human cancer cell line panel established by the NCI Developmental Therapeutics Program to discover novel anticancer drugs; they are frequently studied cancer cell lines. a collection of ORF sequences are introduced into cancer cells through transfection in a multiwell format, and the cells are then exposed to single or combinatory agents before being tested for changes in their viability. an organ-bud grown in vitro, based on stem cells from a particular organ to form a 3D epithelial structure while retaining its tissue identity. a xenograft created when cancerous tissue from a patient's primary tumor is implanted directly into an immunodeficient mouse. These models avoid prior selection in tissue culture and may more closely mimic human cancer compared with cell line-derived xenografts. a member of the protein tyrosine kinases family, containing high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. similar to an ORF screen, but with the ORF libraries replaced by siRNA or shRNA libraries. a situation in which cells can tolerate the loss of one of two genes but their simultaneous inactivation causes lethality. Chemical synthetic lethality screens, drug enhancer screens, or ‘drop out’ screens are all intended to identify ways to achieve synthetic lethality. small-molecule drugs that inhibit tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins that can be regulated by phosphorylation in signal transduction cascades.

Application Of The CRISPR-Cas9 System to Drug Discovery in Breast Cancer

The role of the CRISPR‐Cas system in cancer drug development: Mechanisms of action and therapy

Genetic and Pharmacological Interrogation of Cancer Vulnerability Using a Multiplexed Cell Line Screening Platform

Identification of Drug Resistance Genes Using a Pooled Lentiviral CRISPR/Cas9 Screening Approach

CRISPR Screens in Mechanism and Target Discovery for AML

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

Advancements in CRISPR Screens for the Development of Cancer Immunotherapy Strategies

Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for anti-tumor drug discovery

Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches

Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance

CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response

CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Research progress on the application of CRISPR/Cas9 technology in breast cancer treatment

Harnessing the evolving CRISPR/Cas9 for precision oncology

Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review

Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy